 |
62 Diseases |  |
27 Trials |
|
27 Trials |  |
847 News |  |
| «12345678910» |
- |||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
Trial completion, HEOR, Real-world evidence, Real-world: REGAIN CONTROLt: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (clinicaltrials.gov) - Nov 1, 2017
P4, N=609, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed
- |||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
Trial completion, HEOR, Real-world evidence, Real-world: Reach-Controlt: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Na (clinicaltrials.gov) - Oct 30, 2017
P4, N=705, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Victoza (liraglutide) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion, Trial primary completion date: Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake (clinicaltrials.gov) - Oct 25, 2017
P=N/A, N=26, Completed, Sponsor: Indiana University
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2017
- ||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
Enrollment closed, HEOR, Real-world evidence, Real-world: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM) (clinicaltrials.gov) - Oct 17, 2017
P4, N=3324, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2017 Recruiting --> Active, not recruiting
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: CF-IDEA: Cystic Fibrosis - Insulin Deficiency, Early Action (clinicaltrials.gov) - Oct 4, 2017
P3, N=100, Recruiting, Sponsor: Sydney Children's Hospital Network
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Dec 2018
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial termination, Combination therapy: A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin (clinicaltrials.gov) - Sep 1, 2017
P3, N=42, Terminated, Sponsor: Novo Nordisk A/S
Trial primary completion date: Dec 2016 --> Dec 2018 Completed --> Terminated
- ||||||| Steglatro (ertugliflozin) / Pfizer, Merck (MSD)
Monotherapy: A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). (clinicaltrials.gov) - Aug 29, 2017
P3, N=621, Completed, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated Active, not recruiting --> Completed
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment closed, Enrollment change: Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy (clinicaltrials.gov) - Jul 19, 2017
P=N/A, N=33, Active, not recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting | N=60 --> 33
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P3 trial: Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes. (clinicaltrials.gov) - Jul 18, 2017
P3, N=752, Completed, Sponsor: Novo Nordisk A/S
- |||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: ADAPT: Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes (clinicaltrials.gov) - Jun 1, 2017
P4, N=520, Completed, Sponsor: Novo Nordisk A/S
Enrolling by invitation --> Active, not recruiting | N=60 --> 33 No longer recruiting --> Completed
- | Victoza (liraglutide) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study (clinicaltrials.gov) - May 3, 2017
P4, N=100, Recruiting, Sponsor: University of Texas Southwestern Medical Center
No longer recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: IDIOM: Insulin Detemir in Obesity Management (clinicaltrials.gov) - Apr 18, 2017
P=N/A, N=240, Active, not recruiting, Sponsor: Vanderbilt University
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2015 --> Dec 2017
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment change, Trial termination, Trial primary completion date: Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog (clinicaltrials.gov) - Apr 7, 2017
P4, N=2, Terminated, Sponsor: Laniado Hospital
Trial primary completion date: Dec 2015 --> Dec 2017 N=20 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Feb 2017; Insufficient recruitment rate
- || Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
Trial primary completion date, HEOR, Real-world evidence, Real-world: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM) (clinicaltrials.gov) - Mar 23, 2017
P4, N=3270, Recruiting, Sponsor: Sanofi
N=20 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Feb 2017; Insufficient recruitment rate Trial primary completion date: May 2018 --> Nov 2017
- | Bydureon (exenatide XR once-weekly) / AstraZeneca, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy: Dexlar: Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes (clinicaltrials.gov) - Mar 3, 2017
P4, N=0, Withdrawn, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: May 2018 --> Nov 2017 N=75 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jun 2018
- ||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes (clinicaltrials.gov) - Jan 30, 2017
P3, N=389, Completed, Sponsor: Novo Nordisk A/S
N=75 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jun 2018 No longer recruiting --> Completed
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Phase classification, Combination therapy: Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes (clinicaltrials.gov) - Jan 30, 2017
P3, N=132, Completed, Sponsor: Novo Nordisk A/S
No longer recruiting --> Completed Phase classification: P4 --> P3
- ||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes (clinicaltrials.gov) - Jan 29, 2017
P3, N=503, Completed, Sponsor: Novo Nordisk A/S
Phase classification: P4 --> P3 No longer recruiting --> Completed
- ||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes (clinicaltrials.gov) - Jan 29, 2017
P3, N=324, Completed, Sponsor: Novo Nordisk A/S
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes (clinicaltrials.gov) - Jan 29, 2017
P3, N=447, Completed, Sponsor: Novo Nordisk A/S
No longer recruiting --> Completed No longer recruiting --> Completed
- ||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
Enrollment closed, HEOR, Real-world evidence, Real-world: REGAIN CONTROLt: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (clinicaltrials.gov) - Jan 23, 2017
P4, N=580, Active, not recruiting, Sponsor: Sanofi
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- | Phase classification: Observational Study of Patients Using NovoMix (clinicaltrials.gov) - Jan 9, 2017
P4, N=1569, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Phase classification: P=N/A --> P4
- || New P3 trial: The SUGAR-DIP trial: Oral medication versus insulin for diabetes in pregnancy De SUGAR-DIP trial: Orale medicatie versus insuline voor zwangerschapsdiabetes (EUDRACT) - Dec 21, 2016
P3, N=810, Ongoing, Sponsor: University Medical Center Utrecht
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry (clinicaltrials.gov) - Dec 8, 2016
P=N/A, N=3055, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Phase classification: P=N/A --> P4 N=2055 --> 3055
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy (clinicaltrials.gov) - Dec 7, 2016
P=N/A, N=60, Enrolling by invitation, Sponsor: University of Colorado, Denver
N=2055 --> 3055 Trial primary completion date: Nov 2016 --> Mar 2017
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120) (clinicaltrials.gov) - Dec 1, 2016
P2, N=36, Active, not recruiting, Sponsor: Wake Forest School of Medicine
Trial primary completion date: Nov 2016 --> Mar 2017 Trial primary completion date: Sep 2015 --> Mar 2017
- ||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
New P4 trial, HEOR, Real-world evidence, Real-world: REGAIN CONTROLt: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (clinicaltrials.gov) - Nov 18, 2016
P4, N=580, Recruiting, Sponsor: Sanofi
- ||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
New P4 trial, HEOR, Real-world evidence, Real-world: Reach-Controlt: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Na (clinicaltrials.gov) - Nov 18, 2016
P4, N=680, Active, not recruiting, Sponsor: Sanofi
- || Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment closed: Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics (clinicaltrials.gov) - Nov 2, 2016
P=N/A, N=100000, Active, not recruiting, Sponsor: Biologics & Biosimilars Collective Intelligence Consortium
Trial primary completion date: Sep 2015 --> Mar 2017 Enrolling by invitation --> Active, not recruiting
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change, Combination therapy: A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin (clinicaltrials.gov) - Oct 25, 2016
P3, N=42, Completed, Sponsor: Novo Nordisk A/S
Enrolling by invitation --> Active, not recruiting N=358 --> 42
- ||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
New trial: Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics (clinicaltrials.gov) - Oct 4, 2016
P=N/A, N=100000, Enrolling by invitation, Sponsor: Biologics & Biosimilars Collective Intelligence Consortium
- Trial completion, Phase classification, Enrollment change, Trial primary completion date: Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs (clinicaltrials.gov) - Aug 25, 2016
P1, N=36, Completed, Sponsor: Yale University
N=358 --> 42 Enrolling by invitation --> Completed | Phase classification: PN/A --> P1 | N=75 --> 36 | Trial primary completion date: Apr 2010 --> Sep 2011
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy (clinicaltrials.gov) - Aug 22, 2016
P=N/A, N=60, Enrolling by invitation, Sponsor: University of Colorado, Denver
Enrolling by invitation --> Completed | Phase classification: PN/A --> P1 | N=75 --> 36 | Trial primary completion date: Apr 2010 --> Sep 2011 Trial primary completion date: Jul 2016 --> Nov 2016
- Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion, Trial primary completion date: Basal21: Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes (clinicaltrials.gov) - Aug 16, 2016
P=N/A, N=26, Completed, Sponsor: University of Padova
Trial primary completion date: Jul 2016 --> Nov 2016 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2016
- || Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
Trial primary completion date, HEOR, Real-world evidence, Real-world: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM) (clinicaltrials.gov) - Aug 8, 2016
P4, N=3270, Recruiting, Sponsor: Sanofi
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2016 Trial primary completion date: Nov 2017 --> May 2018
- ||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion, Combination therapy: A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin (clinicaltrials.gov) - Aug 1, 2016
P3, N=358, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Nov 2017 --> May 2018 Recruiting --> Completed
- Metastases: Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy? (clinicaltrials.gov) - Jul 27, 2016
P=N/A, N=40, Not yet recruiting, Sponsor: University of California, San Francisco
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry (clinicaltrials.gov) - Jul 18, 2016
P=N/A, N=2055, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Recruiting --> Completed N=3075 --> 2055
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
New trial: TREAD-DIAB: Evaluation of Glycemic Changes During Exercise in Children With Type 1 Diabetes (clinicaltrials.gov) - Jul 6, 2016
P=N/A, N=40, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
- Januvia (sitagliptin) / Merck (MSD)
Enrollment open, Surgery: Sitagliptin in Non-Diabetic Patients Undergoing General Surgery (clinicaltrials.gov) - Jun 29, 2016
P4, N=80, Recruiting, Sponsor: Emory University
N=3075 --> 2055 Not yet recruiting --> Recruiting
- |||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment open, Combination therapy: A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin (clinicaltrials.gov) - Jun 28, 2016
P3, N=358, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- Victoza (liraglutide) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study (clinicaltrials.gov) - Jun 24, 2016
P4, N=100, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Dec 2016
- | Bydureon (exenatide XR once-weekly) / AstraZeneca, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
New P4 trial, Combination therapy: Dexlar: Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes (clinicaltrials.gov) - Jun 23, 2016
P4, N=75, Recruiting, Sponsor: Weill Medical College of Cornell University
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy (clinicaltrials.gov) - Jun 1, 2016
P=N/A, N=60, Enrolling by invitation, Sponsor: University of Colorado, Denver
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Mar 2016 --> Jul 2016
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open: The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients (clinicaltrials.gov) - May 18, 2016
P2/3, N=80, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial primary completion date: Mar 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- || Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
Trial primary completion date, HEOR, Real-world evidence, Real-world: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM) (clinicaltrials.gov) - Apr 21, 2016
P4, N=3270, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2017 --> Oct 2017
- | Januvia (sitagliptin) / Merck (MSD)
New P4 trial, Surgery: Sitagliptin in Non-Diabetic Patients Undergoing General Surgery (clinicaltrials.gov) - Apr 18, 2016
P4, N=80, Not yet recruiting, Sponsor: Emory University
- Trial primary completion date: Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients (clinicaltrials.gov) - Mar 16, 2016
P4, N=200, Recruiting, Sponsor: Mackay Memorial Hospital
Trial primary completion date: Jul 2017 --> Oct 2017 Trial primary completion date: Nov 2014 --> Aug 2015
- || Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
Trial primary completion date, HEOR, Real-world evidence, Real-world: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM) (clinicaltrials.gov) - Feb 17, 2016
P4, N=3270, Recruiting, Sponsor: Sanofi
Trial primary completion date: Nov 2014 --> Aug 2015 Trial primary completion date: Mar 2017 --> Jul 2017
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy (clinicaltrials.gov) - Jan 19, 2016
P=N/A, N=60, Enrolling by invitation, Sponsor: University of Colorado, Denver
Trial primary completion date: Mar 2017 --> Jul 2017 Trial primary completion date: Dec 2015 --> Mar 2016